Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

Documenti analoghi

• Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells
  di: Patel, Viralkumar, et al.
  Pubblicazione: (2015)
• Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells
  di: Patel, Viralkumar, et al.
  Pubblicazione: (2016)
• Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia
  di: Lamothe, Betty, et al.
  Pubblicazione: (2015)
• Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
  di: Sarkar, Aloke, et al.
  Pubblicazione: (2015)
• Targeting executioner procaspase-3 with the procaspase activating compound B-PAC-1 induces apoptosis in multiple myeloma cells
  di: Zaman, Shadia, et al.
  Pubblicazione: (2015)